Aims: β3-adrenoceptor (β3-AR) agonist is known to relax the detrusor muscles. Considering that both pelvic organ prolapse (POP) and overactive-bladder (OAB) are frequently seen in the elderly population, the effect of β3-AR agonist on the pelvic floor tissues should be investigated. As a first step, this pilot, experimental, and descriptive study was designed to investigate the presence of β3-AR expression in the uterosacral-ligaments (USLs) in postmenopausal (PMP) women with POP.
Methods: After informed consent, PMP women undergoing hysterectomy for POP were recruited for the intraoperative collection of distal USL between 5/2016 and 8/2016. H&E analysis for the USLs and immunohistochemistry (IHC) analysis for β3-AR and α-actin smooth muscle (SM) were carried out. Tissue composition and percentage of β3-AR expression in the USLs were subjectively measured and the staining results were expressed as descriptive analysis.
Results: Total 11 USL specimens were collected and nine specimens were included for the final analysis (one specimen: used for antibody concentration adjustment and one specimen: failed proper staining). Under high-power-field, the USLs were composed of SM cells (81.5 ± 7.47%) and connective tissues (16.5 ± 7.9%). On IHC analysis, six out of nine specimens expressed β3-AR with a different level of expression in SM cells in the USLs.
Conclusions: The majority of distal USLs were composed of SM cells. β3-ARs are expressed in 67% of the study specimens. Considering that both POP and OAB are frequently seen in the elderly population, the effect of β3-AR agonist on the pelvic floor tissues should be investigated further.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/nau.23579 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TRAIL agonists rescue mice from radiation-induced lung, skin or esophageal injury.
J Clin Invest
January 2025
Laboratory of Translational Oncology and Translational Cancer Therapeutics, Warren Alpert Medical School of Brown University, Providence, United States of America.
Radiotherapy can be limited by pneumonitis which is impacted by innate immunity, including pathways regulated by TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from toxic effects of radiation and found two different agonists, parenteral PEGylated trimeric-TRAIL (TLY012) and oral TRAIL-Inducing Compound (TIC10/ONC201) could reduce pneumonitis, alveolar-wall thickness, and oxygen desaturation. Lung protection extended to late effects of radiation including less fibrosis at 22-weeks in TLY012-rescued survivors versus un-rescued surviving irradiated-mice.
View Article and Find Full Text PDFSelective progesterone receptor modulators for the treatment of dysmenorrhea: an update.
Expert Opin Pharmacother
January 2025
Department of Obstetrics and Gynecology, University of Florence, Careggi University Hospital, Florence, Italy.
Introduction: Dysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine tissues (myometrium and endometrium) oral contraceptives are used off-label for treating primary or secondary dysmenorrhea. The development of selective progesterone receptor modulators (SPRMs) a class of synthetic steroids with agonistic, antagonistic, or mixed effects in targeting PRs in different tissues stimulated their possible clinical use for treating secondary dysmenorrhea related to uterine diseases (endometriosis, adenomyosis, uterine fibroids).
View Article and Find Full Text PDFTreatment of bile acid diarrhea with GLP-1 receptor agonists: A Promising Yet Understudied Approach.
Clin Transl Gastroenterol
January 2025
Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Bile acid diarrhea (BAD) is a chronic and socially debilitating disease characterized by abdominal pain, diarrhea, urgency, and fecal incontinence. Recently, in a six-week randomized controlled trial (RCT), we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms. The emergence of new, more potent, and longer-acting GLP-1RAs has spurred an interest in these treatments in BAD management.
View Article and Find Full Text PDFWhy wasn't mirabegron chosen for the first year of the CMS negotiation program?
Urogynecology (Phila)
January 2025
UConn Health, Farmington, CT.
Importance: The most used overactive bladder (OAB) medications are anticholinergics, which professional societies recommend avoiding in older patients given dementia risk. Cost prevents patients from switching to preferred beta-3 agonists. Mirabegron was the only beta-3 agonist eligible for the Centers for Medicare/Medicaid Services (CMS) 2023 Drug Negotiation Program (DNP).
View Article and Find Full Text PDFEffects of tryptophan-selective lipidated GLP-1 peptides on the GLP-1 receptor.
J Endocrinol
January 2025
N Inagaki, Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are widely used as antidiabetic and anti-obesity agents. Although conventional GLP-1 RAs such as liraglutide and semaglutide are acylated with fatty acids to delay their degradation by dipeptidylpeptidase-4 (DPP-4), the manufacturing process is challenging. We previously developed selectively lipidated GLP-1 peptides at their only tryptophan residue (peptide A having one 8-amino-3,6-dioxaoctanoic acid (miniPEG) linker and peptide B having three miniPEG linkers).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!